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Ligand-receptor mediated targeting may affect differently the performance of 
supramolecular drug carriers depending on the nature of the nanocarrier. In this study, 
we compare the selectivity, safety and activity of doxorubicin (Dox) entrapped in 
liposomes versus Dox conjugated to polymeric nanocarriers in the presence or absence 
of a folic acid (FA)-targeting ligand to cancer cells that overexpress the folate receptor 
(FR). Two pullulan (Pull)-based conjugates of Dox were synthesized, (FA-PEG)-Pull-
(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox). The other delivery systems are Dox loaded 
PEGylated liposomes (PLD, Doxil®) and the FR-targeted version (PLD-FA) obtained by 
ligand post-insertion into the commercial formulation. Both receptor-targeted drug 
delivery systems (DDS) were shown to interact in vitro specifically with cells via the folate 
ligand. 
Treatment of FR-overexpressing human cervical carcinoma KB tumor-bearing 
mice with three-weekly injections resulted in slightly enhanced anticancer activity of PLD-
FA compared to PLD and no activity for both pullulan-based conjugates. When the DDS 
were administered intravenously every other day, the folated-Pull conjugate and the non-
folated-Pull conjugate displayed similar and low antitumor activity as free Dox. At this 
dosing regimen, the liposome-based formulations displayed enhanced antitumor activity 
with an advantage to the non-folated liposome. However, both liposomal formulations 
suffered from toxicity that was reversible following treatment discontinuation. Using a daily 
dosing schedule, with higher cumulative dose, the folated-Pull conjugate strongly 
inhibited tumor growth while free Dox was toxic at this regimen. For polymeric constructs, 
increasing dose intensity and cumulative dose strongly affects the therapeutic index and 
reveals a major therapeutic advantage for the FR-targeted formulation. All DDS were able 
to abrogate doxorubicin-induced cardiotoxicity. This study constitutes the first side-by-
side comparison of two receptor-targeted ligand-bearing systems, polymer therapeutics 
versus nanoparticulate systems, evaluated in the same mouse tumor model at several 





For more than a century, since Paul Ehrlich established the "magic bullet" concept 
[1], generations of chemists and pharmacologists have attempted to devise powerful and 
specific anticancer drugs, that go directly to their intended targets yet remain harmless to 
healthy tissues. Despite groundbreaking achievements, most anticancer drugs suffer 
from narrow therapeutic window and cancer still threatens numerous lives owing to its 
multi-dimensional complexity. In recent years, different versatile macromolecular 
systems, commonly defined as nanomedicines, have been designed and developed for 
cancer therapy [2, 3]. Nano-sized carriers can improve the physico-chemical properties 
of low molecular weight drugs enhancing their therapeutic index by altering their 
pharmacokinetics and increasing their accumulation in the target tissue exploiting the 
enhanced permeability and retention (EPR) effect [4, 5]. However, this non-selective 
blood circulation and extravasation-dependent targeted strategy, relying solely on the 
leaky vasculature of tumors is limited due to the heterogeneity of the angiogenic 
vasculature characterizing different tumor types [6]. Therefore, conjugation of targeting 
ligands to nanocarriers might overcome the limitations of non-selective delivery to the 
tumor site, achieving enhanced tumor selectivity and intracellular uptake.  
Drug delivery systems (DDS) include supramolecular assemblies for the (i) physical 
entrapment of drugs, such as liposomes [7, 8] and nanoparticles [9, 10] and (ii) chemical 
covalent binding of drugs, such as polymer conjugates [11, 12], polymeric micelles [13, 
14] and polymersomes [15, 16], named polymer therapeutics [17]. 
Liposomal formulations have proven to be among the most successful approaches 
of drug delivery translated to the clinic. These spheroidal phospholipidic vesicles 
represent a versatile carrier for both hydrophilic and hydrophobic drugs. Due to the simple 
production, efficient drug loading and ease of tailoring of their physico-chemical and bio-
pharmaceutical properties, several liposomal formulations for drug delivery have been 
developed [18]. Nevertheless, the early liposomal formulations were affected by major 
uptake by the reticuloendothelial system (RES), which dramatically reduced the 
circulation half-life [19]. Efforts made to avoid clearance by the immune system [20], 
resulted in the development of long-circulating (“stealth”) liposomal formulations with the 
ability of escaping the RES clearance. The most effective approach is the coating of the 
vesicles surface with poly(ethylene glycol) (PEG) [21], which provides steric hindrance, 
avoidance of opsonization and thus, guarantees a prolonged circulation in the 
bloodstream. These features led to the approval of several liposomal formulations for 
clinical use [22].  
Doxil® is a PEGylated liposomal doxorubicin (PLD) formulation approved for the 
treatment of breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s Sarcoma [22, 
23]. PLD accumulates in cancer tissue via non-selective targeting extravasating through 
the leaky tumor vasculature (EPR effect). Following accumulation in the target tissue, the 
liposomes undergo degradation leading to the release of the entrapped doxorubicin 
4 
 
(Dox), which is then internalized in the cancer cells as free drug [22]. The advantage of 
the liposomal formulation compared to free Dox is the reduced cardiac toxicity, while the 
main adverse effect is the hand-foot syndrome (palmar-plantar erythrodysesthesia), that 
causes redness, swelling, and pain on the palms of the hands and the soles of the feet. 
Another toxicity related to PLD is a pseudo-allergic reaction that might appear after the 
first infusion [22, 24]. 
In parallel, several polymer therapeutics have been developed for the delivery of 
Dox [25-27]. A few of them have reached clinical trials [28-30], however, none of them 
have yet received approval by the main authorities, the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA).  
On the basis of Ringsdorf's polymeric carrier concept [31, 32], we recently 
developed a conjugate of Dox using pullulan as the polymeric backbone [33]. Pullulan is 
a natural, non-ionic and linear homopolysaccharide formed by repeating units of 
maltotriose [34]. It has been used in the formulation of several drug delivery systems [35-
38], due to its biodegradability, low immunogenicity, reduced toxicity and its fair solubility 
in aqueous and a few organic solvents [39]. Furthermore, pullulan bears functional groups 
along the polymer backbone that allow multivalent derivatization with a variety of pendant 
functions [40]. 
Pullulan polymers at the nano scale exploit the leaky tumor vasculature and EPR 
effect to selectively accumulate in cancer tissue [37, 41]. Several pullulan-based delivery 
systems for anticancer drugs have been developed. These include self-assembling 
hydrophobized  pullulan [42], pH-sensitive pullulan nanoparticles [41] and bioconjugates 
[37, 43-45] for the delivery of Dox, camptothecin, paclitaxel, alendronate, cisplatin, 
metothrexate and combretastatin A4. Here, we conjugated Dox to the pullulan backbone 
via an acid sensitive hydrazone bond, which is stable at physiological pH, but hydrolyzes 
under acidic conditions, such as those found in endosomes or an even lower pH in 
lysosomes. The bioconjugate was endowed with targeting properties by introducing folate 
functions in the supramolecular structure. 
In order to confer cellular targeting properties to DDS, many targeting agents have 
been evaluated [46-50]. Folic acid (FA) is an attractive targeting agent to a large number 
of cancer cell types that overexpress the folate receptor (FR). This small molecule lacks 
immunogenicity and can be easily conjugated to supramolecular and macromolecular 
structures. FR-targeted precision nanomedicines can be exploited for the treatment of 
cancers and other difficult-to-treat diseases overexpressing folate receptor, such as 
polycystic kidney disease [51], and inflammatory diseases (e.g. adjuvant arthritis) 
targeting activated macrophages [52]. Thus, folic acid has been widely used for 
conjugation to DDS [22]. Aimed at evaluating the targeting properties of FA, we 
conjugated it both to a doxorubicin-loaded liposome (via ligand post insertion) [53] and to 
a Dox-pullulan conjugate. Previous studies showed that Dox loaded folated liposomes 
and Dox conjugated folated pullulan have suitable biopharmaceutical behaviours that 
make them promising for improved therapeutic performance as compared to the non-
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folated counterparts. However, in view of exploiting these novel drug delivery systems for 
an efficient and targeted cancer treatment, in vitro and in vivo comparative studies were 
undertaken to compare the biopharmaceutical and therapeutic performance of the 
liposomal vs polymeric systems. The comparative studies were performed according to 
advanced and validated in vitro and in vivo protocols, which could provide some 
elucidation the influence of the architecture on the DDS behaviour in terms of efficacy 
and safety. The effect of the supramolecular structures on the antitumor and anti-
angiogenic activity and on the targeting properties conferred by the bound FA was 
investigated testing Dox-equivalent doses in human cancer cell line and on endothelial 
cells as well as in vivo on tumor-bearing mice. 
 
MATERIALS AND METHODS 
Materials 
Doxorubicin hydrochloride was purchased from Iffect Chemphar Co., LTD. (Shenzhen, 
P.R. China). Doxil® was supplied by Johnson & Johnson (New Jersey, USA). [3H]-Folic 
acid (FA) sodium salt was bought from American Radiolabeled Chemicals, Inc. (St. Louis, 
MO, USA). 3,3’-N-(ε-maleimidocaproic acid)-hydrazidetrifluoroacetic acid salt (EMCH) 
was obtained from Molecular Biosciences, Inc. (Boulder, CO, USA). Diaminopolyethylene 
glycol (PEG1900(NH2)2), ∼100 kDa pullulan (Mw/Mn 2.03), folic acid (FA), cholesterol, 
sodium borohydride (NaBH4), N-hydroxysuccinimide (NHS), N,N’-
dicyclohexylcarbodiimide (DCC), and all the solvents were purchased from Fluka (Buchs, 
Switzerland). Cysteamine (Cyst), 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), mannitol, 
sodium cyanoborohydride (NaCNBH3), 2,4,6-trinitrobenzenesulfonic acid (TNBS),, 
triscarboxyethylphosphine (TCEP), dithiothreitol (DTT), masson trichrome, and pullulan 
standard set for gel permeation analyses were obtained from Sigma Chemical Co. (St. 
Louis, MO,USA). Hydrogenated soybean phosphatidyl-choline (HSPC) was purchased 
from Lipoid, (Duisburg, Germany).  Distearoyl-phosphatidylethanolamine conjugated to 2 
kDa monomethoxy-poly(ethylene glycol) (mPEG2000-DSPE) was obtained from Bio-lab 
(Jerusalem, Israel). Folate derivatized mPEG3350-DSPE (FA-PEG3350-DSPE) was 
supplied by Shaare Zedek Experimental Oncology Lab (Jerusalem, Israel). ProLong Gold 
antifade with DAPI mounting medium was purchased from Invitrogen (Eugene, OR, USA). 
Nu/nu mice and folate depleted diet were purchased from Harlan (Rechovot, Israel). All 
tissue culture reagents were purchased from Biological Industries Ltd (Beit Haemek, 










Synthesis of polymeric conjugates of doxorubicin 
 
Pullulan derivatized with PEG and cysteamine (NH2-PEG)-Pull-(Cyst), pullulan 
derivatized with PEG, cysteamine and FA, (FA-PEG)-Pull-(Cyst), pullulan derivatized with 
PEG, cysteamine and Dox, (FA-PEG)-Pull-(Cyst), and pullulan derivatized with PEG, 
cysteamine (Cyst), FA and Dox, (FA-PEG)-Pull-(Cyst-Dox), were synthesized according 




The PEGylated liposomal doxorubicin formulation used in these studies was Doxil®, a 
product of Johnson & Johnson, marketed in Israel by Janssen Pharmaceuticals 
(Shefayim, Israel) in 10 mL vials at a doxorubicin concentration of 2 mg/mL. Control drug-
free PEGylated liposomes (PL) were prepared as reported by Shmeeda et al. [54]. Both 
Doxil® and control liposomes were in the mean size range of 80-100 nm. Folate-
derivatized PEG3350-DSPE (FA-PEG3350-DSPE) was prepared as described previously 
[55]. Ligand post-insertion was performed as previously reported [53].Detailed procedure 
is reported in Supporting Information. 
 
Dynamic light scattering and zeta potential (ζ potential) measurements 
 
The dynamic light scattering (DLS) and ζ potential measurements were performed with a 
ZetaSizer Nano ZS (Malvern instruments, UK). The pullulan conjugates and the 
liposomes samples were diluted in 10 mM phosphate buffer at pH 7.0. The measurements 





Human cervical carcinoma KB cells (HeLa contaminant, LoFR-KB cell line) were 
purchased from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 (Gibco-
InVitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) heat-inactivated foetal 
bovine serum, 2 mM glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin. A 
subline of KB cells overexpressing folate receptor (HiFR-KB cell line) was cultured in FA-
depleted medium (FF-RPMI) supplemented with 10% (v/v) heat-inactivated foetal bovine 
serum, 2 mM glutamine, 100 IU/mL penicillin and 100 µg/mL streptomycin [55]. Human 
umbilical vein endothelial cells (HUVEC) were purchased from Lonza (Visp, Switzerland) 




Folate Competition Study 
HiFR-KB, LoFR-KB or HUVEC cells were seeded at a concentration of 1x106 cells/well in 
a 24 well plate, in 0.5 mL of RPMI (for LoFR-KB), FF-RPMI (for HiFR-KB cells) or EMB-2 
(for HUVEC), with cold FA, (FA-PEG)-Pull-(Cyst) or folated drug-free PEGylated 
liposomes (PL-FA) at 2 µM FA-equivalent dose. Following 3 h of incubation, 10 µL of 
[3H]FA (5 µCi/mL, 10 µM, diluted to a final concentration in each well 0.2 µM) were added 
to each well. Following additional 3 h of incubation, the medium was removed, the cells 
harvested with trypsin and the suspension was centrifuged. The supernatant was 
discarded and the pellet washed 3 times with 10 mM phosphate buffer, 0.15 M NaCl 
(PBS), pH 7.4. After the last wash, each sample was treated overnight with 500 µL of 0.5 
N NaOH, followed by neutralization with 0.5 N HCl. After 30 min, 600 µL of the suspension 
was added to 3 mL of scintillation fluid and the amount of radioactivity was determined 
(Tri-Carb® 2100TR liquid scintillation counter, Waltham, MA, USA).  
Intracellular trafficking of pullulan conjugate and PEGylated liposomal doxorubicin 
HiFR-KB cells were seeded on sterile 13 mm cover glasses in a 24 wells plate 
(1.5 × 105 cells/0.5 mL per well in FF-RPMI) 24 h before incubation with conjugates. 
HiFR-KB cells were incubated with 200 nM Dox, or Dox-equivalent of (FA-PEG)-Pull-
(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD or PLD-FA for different times (5 min, 30 
min, 4 h, 24 h), then washed three times with cold PBS, pH 7.4, fixed with 3.5% 
paraformaldehyde for 15 min at room temperature (RT) and washed again with PBS. For 
counter staining, cells were permeabilized with 0.1% Triton X-100 for 3 min and rinsed 
with PBS, pH 7.4. For confocal imaging of conjugate cellular uptake by KB cells, cover 
glasses were mounted by ProLong Gold anti-fade with DAPI mounting medium. All slides 
were kept at 4°C in dark until confocal microscopy analysis was performed. 
Confocal microscopy 
Cellular uptake, internalization and colocalization of conjugates and liposomes were 
monitored utilizing a Leica TCS SP5 confocal imaging systems with 60x oil objectives. All 
images were taken using a multi-track channel acquisition to prevent emission cross-talk 
between fluorescent dyes. Single XY, XZ plane-images were acquired in 1024×1024 
resolution. Images from Z stack acquisition were processed as separate channels using 
Huygens® deconvolution software and merged as a single image. 
Cell viability studies 
The HiFR-KB cells were seeded in 96-well tissue culture plates at a density of 2×103 
cells/well in FF-RPMI. After 24 h, the culture medium was replaced with 100 µL of medium 
containing serial increasing concentrations (0.01 nM–100 µM) of Dox or Dox-equivalent 
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(FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD, PLD-FA. The plates were 
incubated for 72 h (long-term exposure) or alternatively after 1 h (short-term exposure) 
the treatments were removed, and the cells washed with 200 µL of PBS, pH 7.4. The cells 
incubated for 1 h were further incubated for 72 h in drug free medium. After 72 h, 20 µL 
of a 5 mg/mL MTT solution in PBS, pH 7.4, was added to each well. The plates were 
incubated for 5 h at 37°C, and then the medium was replaced with 200 µL of DMSO. The 
plates were maintained under gentle stirring for 1 h, and the optical absorbance was 
measured at 570 nm using SpectraMax M5e Microplate Reader (Molecular Devices, LLC. 
Sunnyvale, CA, USA) 
Anti-angiogenic activity on HUVEC 
Endothelial cell proliferation assay  
HUVEC (1.5×104 cells/0.5 mL per well) were plated onto 24 well plates in EBM-2 
supplemented with 5% FBS. After incubation for 24 h, cells were exposed to serial 
concentrations of Dox or Dox-equivalent (FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-
(Cyst-Dox), PLD, PLD-FA dissolved in EGM-2. Following 72 h of incubation, HUVEC 
were trypsinized and counted by Z1 Coulter® Particle Counter (Beckman Coulter™). 
Alternatively the cells were treated for 30 min, then incubated for 72 h in EGM-2 drug-
free medium and counted by Coulter Counter. 
Evaluation of anti-tumor activity and toxicity of the conjugates 
All animal procedures were performed in compliance with Tel Aviv University, Sackler 
School of Medicine guidelines and protocols approved by the institutional animal care and 
use committee (IACUC). 
In vivo tumor targeting evaluation 
Nu/nu female mice (6 week old) were inoculated to the right flank with 1 × 106 HiFR-KB 
cells. Mice were fed with a folate-free diet 7 days prior to tumor inoculation and the 
standard diet was resumed 2 days after first treatment. Mice bearing ~40 mm3 tumors 
were treated intravenously (i.v.) with three weekly injections of 5 mg/kg (cumulative dose 
15 mg/kg) of Dox or Dox-equivalent of (FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-
Dox), PLD, PLD-FA. Tumor progression was monitored by caliper measurement 
(width2 x length x 0.52) twice a week. Body weight and tumor size were monitored twice 
a week (n = 8 mice/group). In a second experiment, nu/nu female mice were inoculated 
in the right flank with 1 × 106 HiFR-KB cells. Mice were fed with a folate-free diet 7 days 
prior to tumor inoculation and the standard diet was resumed 2 days after first treatment. 
Mice bearing ~40 mm3 tumors were treated i.v. every other day with 5 mg/kg Dox-
equivalent (cumulative dose 15 mg/kg) of Dox or (FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-
Pull-(Cyst-Dox), PLD, PLD-FA. Tumor progression was monitored by caliper 
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measurement (width2 x length x 0.52) every other day. Body weight and tumor size were 
monitored every other day (n = 12 mice/group, average of two independent experiments). 
In a third experiment, mice nu/nu female mice were inoculated in the right flank with 1 × 
106 HiFR-KB cells. Mice were fed with a folate-free diet 7 days prior to tumor inoculation 
and the standard diet was resumed 2 days after first treatment. Mice bearing 
~40 mm3 tumors were treated i.v. with six injections (on day 1, 2, 3 and 6, 7, 8) each of 5 
mg/kg (cumulative dose 30 mg/kg) of Dox or (FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-
(Cyst-Dox) (Dox-equivalent dose). Tumor progression was monitored by caliper 
measurement (width2 x length x 0.52) every other day. Body weight and tumor size were 
monitored every other day (n = 6 mice/group). In all the experiments, humanitarian end 
point was set at 20% body weight loss, or 800-1000 mm3 tumor size. All the i.v. injections 
were performed via the tail vein. The pullulan polymers and liposomes were all dissolved 
in sterile saline. A control group was injected with saline.   
Echocardiography Examination  
Mice treated every other day with 5 mg/Kg (cumulative dose 15 mg/Kg) of Dox or Dox-
equivalent dose of (FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD, PLD-FA, 
were anesthetized with 2% isoflurane and echocardiograms were performed with a 
commercially available mouse 2D-echocardiography system (Vevo 2100, VisualSonics, 
Toronto, Canada) equipped with 35 MHz phased array transducer. Transthoracic 
echocardiography was performed, 10 days after the last treatment, as previously 
described [56]. An experienced technician, blinded to the treatment groups, performed all 
measurements that were averaged for 3 consecutive cardiac cycles. 
Histological analysis 
After functional evaluation, animals were euthanized with an overdose of pentobarbital 
and hearts were perfused with 4% formaldehyde (15 mmHg) for 10 min. Hearts were 
harvested, sectioned and adjacent blocks were embedded in paraffin, sectioned into 5-
μm slices. To evaluate pathological changes in cardiac morphology and structure, heart 
sections were stained with Masson’s Trichrome.  
Statistical methods 
Data were expressed as mean ± SD for in vitro assays or ± SEM for in vivo. Statistical 
significance was determined using two-way ANOVA. Because of the relatively small 
number of animals in each echocardiography study, echocardiography and histology data 
were compared by one-way ANOVA with Tukey's test. The Kaplan-Meier method and 





Synthesis and characterization of drug delivery systems of doxorubicin 
 
The Dox- and FA-derivatized pullulan [(FA-PEG)-Pull-(Cyst-Dox); Figure 1A] and Dox-
derivatized pullulan [(NH2-PEG)-Pull-(Cyst-Dox)] were synthesized according to the 
procedure reported before [33]. Spectrophotometric analyses showed that the (NH2-
PEG)-Pull-(Cyst) contained 4.8 mol% FA and 3.4 mol% Dox, with respect to the glucose 
units, while (NH2-PEG)-Pull-(Cyst) contained 2.1 mol% Dox. Control drug-free pullulan 
derivatives with FA [(FA-PEG)-Pull-(Cyst); 5 mol% FA)] or without FA [(NH2-PEG)-Pull-
(Cyst)] were also synthesized. Table I reports the complete composition of the polymer 
conjugates. The main physico-chemical properties, namely apparent size and ζ potential 
are reported in Table III. Both pullulan bioconjugates displayed similar molecular weight 
(~ 150 kDa apparent molecular weight, polydispersity - Mw/Mn 1.8) and negative ζ 
potential.  
The folated liposomal formulation of Dox (PLD-FA, Figure 1B) was prepared via ligand 
post insertion of folate conjugated DSPE on the surface of commercial Dox-loaded 
PEGylated liposomes (Doxil®). The Dox and FA contents in PLD-FA were 13.9 mol% and 
0.3 mol%, respectively. Dox content in the non-folated PLD was 14.5 mol%. Drug-free, 
FR-targeted liposomes (PL-FA), and drug-free non-folated liposomes (PL) were also 
prepared as references. Table II reports the composition of liposomal formulations. The 
physico-chemical properties of the liposomal formulations, namely size and ζ potential 
are reported in Table III. All liposomal formulations displayed similar size profiles (~ 80 
nm) and negative ζ potential.  
 
FR-targeted drug delivery systems are internalized via receptor-mediated uptake in 
FR-overexpressing cells.  
The FR receptor-mediated cell uptake selectivity of folated and non-folated delivery systems was 
investigated by competitive studies according to a validated protocol. Following three hours of 
incubation with [3H]FA, KB cells cultured in folate-depleted media (HiFR-KB cells) were 
highly radioactive (17259 ± 2192 dpm), while KB cells cultured in regular RMPI (LoFR-
KB) and HUVEC grown in EBM-2 medium were negligibly radioactive (125 ± 50 dpm and 
25 ± 1.6 dpm respectively) (compared with HiFR-KB, p<10-6). The competitive incubation 
of HiFR-KB cells with [3H]FA and cold (non-radiolabelled) FA, (FA-PEG)-Pull-(Cyst) or 
PL-FA showed a dramatic decrease in cell radioactivity (p<10-9) (Figure 2A) suggesting 
that the nanoconjugates are internalized via FR-mediated endocytosis.  
Dox internalization kinetics to HiFR-KB cells was assessed by laser scanning confocal 
microscopy (LSCM). Free Dox was rapidly internalized by diffusion into cells, and 
localized in the nucleus (Figure 2B). (FA-PEG)-Pull-(Cyst-Dox) conjugate internalized 
within 5 min into the cells (Figure 2B), in agreement with our previously published results 
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in live cells [33]. Following endosomal escape and the release of free Dox from the 
polymer, Dox localized in the nucleus within 240 min (Figure 3). Non-folated (NH2-PEG)-
Pull-(Cyst-Dox) conjugate undergoes slower internalization (240 min, Figure 2B). 
Similarly, the liposomal cell internalization was found to depend on the presence of FA. 
A significant amount of PLD-FA internalized in 4 h, while the non-folated PLD was not 
taken-up by the cells at this time.  
 
(FA-PEG)-Pull-(Cyst-Dox) conjugate and PLD-FA inhibit the proliferation of human 
cervical carcinoma overexpressing the folate receptor (HiFR-KB) and human 
umbilical vein endothelial cells (HUVEC). 
The pharmacological activity of (FA-PEG)-Pull-(Cyst-Dox) and PLD-FA was evaluated 
using HiFR-KB cells and HUVEC. Free Dox was used as control. Studies were carried 
out either by prolonged or by short-term (72 h and 1 h, respectively) cell incubation with 
the Dox formulations. In the case of short-term incubation, after 1 h exposure to treatment 
the medium was replaced with fresh medium followed by 72 h of continued culture. IC50 
values were graphically extrapolated from the viability plots reported in Figure 3 and 
approximated to the closest round value. 
HiFR-KB cell growth inhibition curves obtained by prolonged and short-term drug 
exposure are shown in Figures 3A-3B, and IC50 values are summarized in Table IV. 
Following 72 h exposure to treatments, IC50 values of (FA-PEG)-Pull-(Cyst-Dox) and 
(NH2-PEG)-Pull-(Cyst-Dox) were about 50 and 5000 fold higher than free Dox, 
respectively (significant difference between folated and non-folated pullulan 
bioconjugates at p<10-4). IC50 values obtained following short-term exposure to (FA-
PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox) were 80 and 400 fold higher 
compared to free Dox, respectively (significant difference between folated and non-
folated pullulan bioconjugates p<10-7). IC50 values obtained following short-term cell 
incubation of PLD-FA and PLD were similar to those obtained with the pullulan 
bioconjugates, while the prolonged cell incubation with PLD or PLD-FA resulted in 275-
fold higher IC50 compared to free Dox (p=0.005). 
Results of a similar experiment evaluating the inhibitory effect of the formulations on 
HUVEC proliferation are summarized in Table IV. IC50 values of long-term exposure to 
(FA-PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox) were about 20 and 400 fold 
higher than that obtained with free Dox, respectively (significant difference between 
folated and non-folated pullulan bioconjugates at p<10-14) (Figure 3C), while following 
short-term incubation, it was about 5 and 200 fold higher than Dox (significant difference 
between folated and non-folated pullulan bioconjugates at p<10-5) (Figure 3D). The IC50 
values obtained following prolonged cell exposure to PLD-FA and PLD were 150 and 300 
fold higher than Dox (significant difference between PLD-FA and PLD at p<10-5) (Figure 




higher IC50 compared to free Dox, respectively (significant difference between PLD-FA 
and PLD at p<10-5) (Figure 3D). 
The therapeutic index of (FA-PEG)-Pull-(Cyst-Dox) conjugate and PLD-FA depends 
on their dosing schedule in vivo 
In vivo antitumor efficacy was evaluated using nu/nu mice inoculated with human HiFR-
KB cells. The animals were fed with folate-depleted diet for 7 days before tumor cell 
inoculation and 7 days following tumor inoculation, in order to upregulate the expression 
of FR on cancer cells. Mice were treated three times with the Dox formulations according 
to two treatment schedules: a weekly and an alternate day i.v. administration. In addition, 
the pullulan conjugates, which were found non-toxic under the dosage regimen of 
previous experiments were injected six times at a daily dosing schedule (injections on 
days 1, 2, 3, 6, 7, 8). Free Dox was also administered as a reference. 
Three weekly i.v. injections of 5 mg/Kg Dox-equivalent dose of PLD and PLD-FA strongly 
inhibited tumor growth rate and prolonged survival compared to saline (time by treatment 
interaction resulted at p=0.046 and Log-rank p=0.004 for PLD, p=0.011 for Dox and 
p=0.0002 for PLD-FA compared with saline).The folated liposomal formulation displayed 
higher activity and survival rate compared to the non-folated counterpart. The pullulan 
conjugates, at this dosing schedule, did not show any anticancer activity or advantage 
compared to saline (Figure 4A, C). With this treatment regimen, all the formulations were 
safe and did not cause body weight loss (Figure 4B). 
 
Three treatments every other day with 5 mg/kg Dox-equivalent dose of Dox, (FA-PEG)-
Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD or PLD-FA inhibited tumor growth rate 
(Figure 5A). The ability of PLD and PLD-FA to decrease tumor size appeared only 6 days 
after treatment initiation, probably as a result of increased half-life and sustained drug 
release from these liposomal formulations. Tumor growth inhibition was seen as soon as 
3 days following treatment initiation with the pullulan conjugates. (FA-PEG)-Pull-(Cyst-
Dox) showed a slight advantage compared to the non-folated (NH2-PEG)-Pull-(Cyst-Dox) 
up to 10 days after treatment discontinuation (Figure 5B). This dosing schedule caused 
several toxic deaths for the animals treated with Dox and PLD, while PLD-FA had a lower 
toxicity, in accordance with previous reports [53] (Figure 5D). For these groups, body 
weight loss (≥10% of initial weight) was reported for the mice treated with Dox, PLD and 
PLD-FA (Figure 5C). However, this toxicity was reversible following treatment 
discontinuation resulting in longer overall survival compared with saline for the groups 
that were initially treated with Dox (p=0.05), PLD (p=0.0005) and PLD-FA (p=0.0046) and 
survived the days of treatment (Figure 5E). (FA-PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-
Pull-(Cyst-Dox) inhibited tumor growth to a lesser extent but did not cause body weight 
loss (Figure 5C). These findings suggested that the dose of (FA-PEG)-Pull-(Cyst-Dox) 
and (NH2-PEG)-Pull-(Cyst-Dox) can further be increased in order to obtain a better 




As the pullulan conjugates were safe at the previous studies, a third experiment was 
undertaken at a schedule administration of six i.v. injections of 5 mg/kg Dox-equivalent 
dose of Dox, (FA-PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox). This dosing 
regimen improved the anticancer activity of the pullulan conjugates. In particular, the FR-
targeted (FA-PEG)-Pull-(Cyst-Dox) showed tumor growth inhibition of 96% compared to 
the saline control (p<10-12), and 94% compared to the non-folated polymer Pull-PEG-Dox 
on day 19 (Figure 6A) when all treatment groups were still in the study. All treatments, 
Dox, (FA-PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox), caused body weight 
loss to a different extent (up to 20%, 13% and 9%, respectively) (Figure 6B). The body 
weight loss was non-reversible for mice treated with free Dox and all the mice treated with 
Dox died soon after the last treatment (Figure 6C). On the contrary, the mice treated with 
the pullulan conjugates gained weight immediately after the last treatment, and the 
survival was significantly extended compared to Dox-treated mice and the saline group 
(p=0.0018 and p=0.0014 respectively) (Figure 6C). The higher cumulative dose and the 
more frequent injections significantly improved the outcome of this dosing regimen for 
(FA-PEG)-Pull-(Cyst-Dox), suggesting not only a reduction of toxicity, but also a clear 
beneficial effect of FR-targeting compared to the non-folated (NH2-PEG)-Pull-(Cyst-Dox) 
conjugate. 
 
Pullulan conjugates and liposomal formulations attenuate Dox-induced 
cardiotoxicity 
Preliminary results from echocardiography study showed that the animals treated with 
Dox (three times every other day, cumulative dose of 15 mg/kg), developed left ventricle 
(LV) dysfunction, with an increase in LV systolic area compared to the animals treated 
with saline (Figure 7A). Furthermore, animals treated with free Dox experienced the 
lowest ejection fraction (Figure 7B). Examination of the slides stained with Masson-
Trichrome showed that LV from Dox-treated animals were enlarged (Figure 7C) (n=4). 
Mice treated with saline, liposomal formulations or pullulan conjugates developed less 
adverse LV remodeling, with smaller LV area and greater wall thickness, compared with 
those treated with Dox. Histological staining of hearts with Masson-Trichrome revealed 
that left ventricle average surface area was 3.83 ± 1.00 mm2 for saline, 3.76 ± 1.2 mm2 
for PLD and 2.72 ±1.2 mm2 for PLD-FA, 4.00 ± 1 mm2 for (NH2-PEG)-Pull-(Cyst-Dox) and 
3.72 ± 0.72 mm2 for (FA-PEG)-Pull-(Cyst-Dox), 5.55 ± 0.44 mm2 for Dox (p=0.08). 
DISCUSSION 
Two different Dox delivery systems, liposomal formulations (PLD and PLD-FA) [22, 57] 
and pullulan conjugates [(NH2-PEG)-Pull-(Cyst-Dox) and (FA-PEG)-Pull-(Cyst-Dox)] [33], 
have been compared in vitro and in vivo in order to assess the advantages and 
disadvantages of their use for tumor targeting. As in other comparative studies [58, 59], 




The pullulan conjugates were designed to obtain supramolecular systems with suitable 
physico-chemical and biopharmaceutical properties for non-selective blood circulation 
and extravasation-dependent delivery as well as receptor-targeted Dox delivery to solid 
tumors. Due to their smaller size and “elastic spaghetti coil-like” structure compared to 
the globular particulated liposomes, polymers can easily penetrate into cancer tissue 
though the leaky vasculature [22]. Nevertheless, for the same structural reasons, polymer 
bioconjugates undergo faster clearance compared to PEGylated liposomes. FA was 
conjugated to the polymer backbone [(FA-PEG)-Pull-(Cyst-Dox)] to endow a derivative 
with receptor-mediated tumor targeting ability. Dox was conjugated through a pH-
sensitive bond that can be selectively cleaved under acidic conditions in the lysosomes, 
bestowing biopharmaceutical stability in non-target tissues, namely in the bloodstream, 
and site selective intracellular drug release. 
Doxil® is a PEGylated liposomal formulation of Dox, approved for the treatment of breast 
cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. This vesicular carrier 
allows for high Dox loading, while PEG on the liposome's surface conveys stealth 
properties prolonging its plasma half-life, which is related to the accumulation in the tumor 
tissue [22]. Similarly to (FA-PEG)-Pull-(Cyst-Dox), the commercial formulation decoration 
with FA moieties was performed to bestow liposomes with receptor-mediated targeting 
properties.  
The polymeric and liposomal formulations differ in the amount of FA loading. Each chain 
of (FA-PEG)-Pull-(Cyst-Dox) bears an average of 4.8 FA units, while each PLD-FA is 
decorated with about 100-250 FA molecules per vesicle [55]. Considering the molar 
composition of the two formulations, the Dox:FA ratio in the pullulan formulation is ~0.7, 
while it is ~50 in the liposomes, due to the high Dox loading. Nevertheless, previous 
studies showed that these compositions yielded delivery systems with suitable 
biopharmaceutical features and few preliminary data showed their potential therapeutic 
efficiency. The different payloads of FA guarantees the binding to the FR for both the 
formulations, as shown in the in vitro binding assays. This is in agreement with other 
formulations bearing folic acid that show that this loading degree guarantees binding to 
FR. It is worth to note that studies reported in the literature showed that the optimal 
binding can be achieved at even lower folic acid loading [60, 61]. However, the optimal 
degree of surface substitution reasonably depends on the overall composition and 
physical properties of the DDS, including length of PEG used as spacer. 
First, we investigated the targeting properties conveyed by FA to the pullulan and 
liposomal formulations. FA is a small molecule widely used to achieve tumor targeting by 
direct conjugation to several anticancer agents [62-64] or to colloidal high molecular 
weight DDS such as polymer therapeutics [65, 66] and liposomal formulations [54, 67] as 
it can promote tumor cell receptor-mediated internalization of drugs and colloidal drug 
carriers [33, 55]. Accordingly, FA functionalized colloidal DDS have been found to exhibit 
FR-mediated cytotoxicity and in vivo antitumor effect [68, 69]. Interestingly, the 
conjugation of FA to a low MW agent via a short linker compared to that via a series of 
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long linkers (PEG5000, PEG20000 and PEG60000) gave the best results in terms of improving 
tumor penetration rate and accumulation [70]. 
The ability of FA to promote receptor-mediated internalization of drugs and colloidal drug 
carriers was shown in previous studies [33, 55] and was confirmed by a competition assay 
on human cervical carcinoma KB cells, which overexpress the folate receptor when 
cultured in folate-depleted medium.  
HiFR-KB cells highly internalize the radioactive FA, ([3H]FA), while the internalization is 
negligible in LoFR-KB cells. Competitive studies performed by simultaneous cell 
incubation with [3H]FA and (FA-PEG)-Pull-(Cys) or PL-FA showed that the intracellular 
radioactivity dramatically decreases (Figure 2A) demonstrating that the folated DDS 
compete with the radioactive FA for receptor-binding and cell internalization. 
The internalization profiles of the DDS in HiFR-KB were followed by confocal microscopy, 
recording the fluorescence of Dox conjugated to the polymers or encapsulated in the 
liposomes. As previously reported [33], Dox undergoes rapid cellular internalization (5 
min), showing colocalization with DAPI in the nucleus within 30 min (Figure 2B). After 4 
h incubation with 200 nM Dox, high levels of cell death occurred. The non-folated DDS, 
(NH2-PEG)-Pull-(Cyst-Dox) and PLD, were not yet internalized within 4 h, indicating that 
these systems undergo slow endocytosis. The internalization of the FR-targeted pullulan 
conjugate, (FA-PEG)-Pull-(Cyst-Dox), was observed within 5 min of incubation [33], 
correlating to the fast FR-mediated endocytotic mechanism. Following endosomal 
escape, the free drug is released to the cytoplasm and then gains access to the nucleus 
within 4 h. The uptake of PLD-FA required longer incubation with the HiFR-KB cells 
compared to the (FA-PEG)-Pull-(Cyst-Dox) presumably because of structural constraints 
and slower internalization process. 
The dynamic light scattering (DLS) analysis showed two populations of pullulan 
bioconjugates in buffer, where one population is small and the size of the other population 
is larger than the liposomes. Previous studies showed that the bioconjugate assembling 
is mainly due to the presence of folic acid along the backbone that promotes hydrophobic 
interactions. Therefore, it is possible that polymer bioconjugates undergo disassembling 
and unfolding in the physiological medium of cell incubation and this new extended 
conformation may favor the FA exposure for FR recognition and cell internalization. 
Liposomes, though smaller than the bigger population of the pullulan bioconjugates in 
buffer, maintain their vesicular structure and that may slow down their FR-mediated transit 
through the cell membrane. 
The in vitro cell selectivity and anticancer activity of the DDS was shown with human 
cervical carcinoma HiFR-KB cells, which overexpress the folate receptor. By long-term 
exposure (72 h cell incubation), the FR-targeted pullulan derivative was much more active 
than the non-folated counterpart. After long-term exposure, the FR-targeted pullulan 
conjugate, (FA-PEG)-Pull-(Cyst-Dox), exhibited an IC50 of 20 nM (Figure 3A, Table III). 
The IC50 value of (NH2-PEG)-Pull-(Cyst-Dox) (2000 nM) was 100-fold higher than that of 
(FA-PEG)-Pull-(Cyst-Dox) while the IC50 of free Dox was 0.4 nM.  
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In LoFR-KB cells, after 72 h incubation, the IC50 value of (NH2-PEG)-Pull-(Cyst-Dox) 
(2000 nM) was 50-fold higher than that of (FA-PEG)-Pull-(Cyst-Dox) (Figure S1). The 
different cytotoxicity profiles resulting from long-term treatment with FR-targeted and non-
folated pullulan conjugates might be ascribed to a combination of events, which include 
the different internalization rate and pathway, as well as the different drug release 
kinetics. These events reflect the conjugate composition, namely the presence or 
absence of the targeting agent and the drug loading. Indeed, the folated conjugate can 
be rapidly taken-up by the cells through a receptor-mediated process that involves the 
caveolar pathway, while its non-folated counterpart is taken-up by cells via a non-
selective endocytotic mechanism. Furthermore, although the long-term incubation may 
minimize the differences in cell internalization related to the different uptake processes, it 
should be noted that the pullulan conjugates have negative ζ potential, -5.43 ± 0.84 mV 
for (FA-PEG)-Pull-(Cyst-Dox) and -4.94 ± 0.64 mV for the non-folated polymer (NH2-
PEG)-Pull-(Cyst-Dox). Therefore, the non-folated conjugate interaction with the negative 
surface of the cells is limited due to charge repulsion and thus, non-selective endocytosis 
of this derivative can be further inhibited.  
Finally, according to the bioconjugate design, the pullulan bioconjugates were found to 
be stable under physiological medium [33], indicating that Dox is not released in the 
extracellular medium where the non-folated derivative stay longer than the rapidly cell 
internalized folated bioconjugate, thus preventing cell uptake of free Dox. In contrast to 
the pullulan bioconjugates, long-term incubation of HiFR-KB cells with PLD and PLD-FA 
yielded similar IC50 values for both (200 nM). Although PLD-FA is more rapidly and 
extensively internalized via the FR than PLD, the long-term cell exposure to the 
formulation can yield similar cytotoxic activity possibly due to slow drug release in the 
extracellular medium via leakage from the liposomal formulation and subsequent cellular 
internalization of free drug.  
Similar results were obtained on the LoFR-KB cells treated with the liposomal 
formulations (Figure S1). The short-term exposure (1 h incubation of HiFR-KB cell with 
the Dox formulations followed by 72 h cell incubation in drug-free medium) (Figure 3B) 
also shows the effect of FA on cell targeting and uptake. Following short-term exposure, 
both FR-targeted conjugate and FR-targeted liposome exhibited higher activity (5-fold) 
compared to the non-folated carriers (Table IV). Long-term exposure discriminates better 
between FR-targeted and non-folated pullulan conjugates than between the liposomal 
formulations (Figure 3A).These results confirm the data obtained by long-term cell 
incubation with the pullulan conjugates and show that the bioconjugate selectivity is well-
observed by prolonged cell exposure. The differences displayed between FR-targeted 
and non-folated liposomes confirm the selective and faster cell uptake of the former 
observed by competitive assay and confocal microscopy, and indicate that in 1 h the drug 
is not significantly released in the extracellular medium.  
Next, the anti-angiogenic potential of the pullulan conjugates and the liposomal 
formulations was evaluated in vitro on HUVEC. Unexpectedly, the cytotoxicity results 
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obtained by long-term and short-term cell treatment were intriguing as they resembled 
the results obtained with HiFR-KB cells, suggesting that FA promotes the HUVEC uptake 
of the FR-targeted DDS. Actually, even though two studies reported that HUVEC express 
the FR [71, 72], our findings from the internalization assay with [3H]FA showed that 
HUVEC do not have strong capacity to internalize the folated carriers (Figure 2A). We 
hypothesized that FA could be toxic to HUVEC, but treatment with FA alone did not inhibit 
HUVEC proliferation (Figure S2). Therefore, the data obtained in this study seems to 
suggest that in the case of HUVEC, FA activates a cell uptake process, which parallels 
the one involved in the FR-mediated uptake of [3H]FA. Indeed, It has been reported before 
that FA has anti-angiogenic activity on endothelial cells, inhibiting proliferation and 
reducing tube formation, although at high concentrations [73].” 
Since we found increased HUVEC cytotoxicity for the folated-polymeric systems, we 
evaluated the anti-angiogenic potential of all formulations with an in vitro capillary-like 
tube formation assay (Figure S4). Dox is not reported to inhibit the tube formation and 
neither the liposomal formulations nor the polymeric conjugates were able to enhance the 
anti-angiogenic activity. In this case, no difference was observed between the FR-
targeted and non-folated systems as none of the compounds evaluated were active.  
Then, the in vivo antitumor efficacy of all four drug delivery systems was examined in the 
human KB nu/nu mouse model. Tumor growth, weight loss and survival rate were 
assessed. In the first study, following three once-weekly treatments, both PLD and PLD-
FA exhibited high antitumor efficacy reducing the tumor growth rate and increasing 
survival, as compared to the control (untreated) animals, where the folated liposomal 
formulation was even more efficacious than the non-folated formulation. This improved 
activity of the folate receptor-targeted liposomal formulation has been reported earlier for 
a different dosing regimen of Dox (single injection of 10 mg/kg versus our three weekly 5 
mg/kg regimen at a different folic acid loading of 0.03% versus our 0.3%) [61] and route 
of administration (i.p. versus our i.v.) [74]. Following our dosing regimen, the non-folated 
liposomes showed similar tumor growth rate inhibition, body weight decrease and survival 
rate as free Dox. Our results seem to contradict previous reports, in which non-targeted 
liposomes showed improved anticancer activity compared with free Dox [53, 61], however 
the dissimilar results might be ascribed to the different treatment conditions, namely the 
administration regimen. In this case, the two pullulan bioconjugates were ineffective 
showing similar tumor growth and animal survival rate profiles as the mice treated with 
saline. No weight loss was registered during the three weeks of the treatment for all the 
groups. The higher efficacy of the liposomal formulations as compared to the polymer 
bioconjugates can be explained by the different pharmacokinetic profiles of the two 
formulations. Previous studies showed that the bioconjugates undergo relatively rapid 
clearance from the bloodstream as about 50% of the injected formulation disappears from 
the circulation in about 2 h [33], while the half-life of PEGylated liposomes in mice is 19 h 
[75]. The prolonged stability in the bloodstream of the liposomes are reflected in higher 
accumulation in the tumor mass than found with the polymer bioconjugates. 
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The previous experiment was designed according to the classical dosing schedule and 
optimized for the long-circulating liposomal formulations. A second study (Figure 5), with 
a dosing schedule more adapted to polymer therapeutics which have a shorter half-life 
pharmacokinetic profile [33] was performed, administering a total of 3 treatments every 
other day, i.e. the same cumulative dose but using a higher dose intensity. Although free 
Dox, PLD and PLD-FA were effective in reducing tumor size (Figure 5A), severe weight 
loss and a high number of toxic deaths were observed in animals treated with these 
compounds (Figure 5B, C). Surprisingly, under this dosage regimen, the folated 
liposomes were less effective than the non-folated formulation. This seems to indicate 
that frequent administration of the Dox-loaded liposomes may cause a continuous feeding 
of the tumor, where the targeting properties become irrelevant, while the presence of the 
targeting agent can even reduce the accumulation of the carrier in a massive tumor mass. 
The toxicity of the liposomal formulation was reversible once the treatment was 
discontinued, and the overall survival was prolonged both for PLD and PLD-FA for those 
mice that survived the treatment period, even though PLD-FA reduced the number of 
toxic deaths compared to the non-folated PLD (Figure 5C). Both pullulan conjugates, 
[(FA-PEG)-Pull-(Cyst-Dox) and (NH2-PEG)-Pull-(Cyst-Dox)] were not toxic (Figure 5B, 
C), and displayed similar antitumor efficacy to free Dox without relevant differences 
between the folated and non-folated form (Figure 5A). These data taken together, suggest 
that a higher dose of pullulan conjugates, as opposed to the liposomal formulations, can 
be administered in order to obtain higher anticancer activity and limited toxicity.  
Accordingly, in the third study, mice were treated with the polymer conjugates with an 
even more intense dosing schedule (three daily injections and another three daily 
injections after 3 more days) and with a higher cumulative dose (30 mg/kg Dox-equivalent 
dose). Here, the FR-targeted (FA-PEG)-Pull-(Cyst-Dox) becomes an effective anticancer 
agent, reducing tumor growth up to 94% compared to non-treated mice (Figure 6A). At 
this dosing schedule, the mice treated with the free Dox showed high irreversible weight 
loss (up to 20%) (Figure 6B), leading to rapid toxic death of all the mice treated with Dox 
(Figure 6C). On the contrary, the mice treated with the pullulan-based delivery systems 
showed moderate and reversible body weight loss following treatment discontinuation 
(Figure 6B). The polymeric carriers improved survival up to 50 days following treatment 
initiation (Figure 6C).  
Cardiotoxicity is one of the most severe adverse effects caused by Dox treatment, and 
several parameters have been reported to correlate with myocarditis induced by 
treatment with the free drug [76, 77]. The ability of drug delivery systems to reduce 
cardiotoxicity was evaluated by echocardiography and histological examination of the 
hearts of the treated animals by an experienced radiology technician and cardiologist. 
The echocardiography scan was performed on a small number of mice (n=2-3/group), 
due to high animal mortality and therefore, the statistical evaluation of the experiment is 
limited. Nevertheless, the echocardiography scan and the histological analysis of the 
hearts (including those who died during the experiment) suggest that all liposomal and 
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polymeric formulations tested in this study reduce the cardiotoxicity related to Dox 
therapy. For PLD, this is well known from clinical experience [24, 78]. The mice treated 
with free Dox developed adverse remodeling, especially in the systolic phase (Figure 7A), 
and impaired contractility reflected by impaired left ventricle ejection fraction (EF) (Figure 
7B), compared with mice treated with saline and with the drug delivery systems. In 
particular, the hearts of the mice treated with PLD, PLD-FA, (NH2-PEG)-Pull-(Cyst-Dox) 
and (FA-PEG)-Pull-(Cyst-Dox) (Figure 7C) showed smaller left ventricle (LV) volume and 
greater ventricle wall thickness, compared to free Dox-treated mice, suggesting that 
liposomal and polymeric nanomedicines are safer than free Dox and can prevent Dox-
induced cardiotoxicity as already shown clinically for PLD [78]. These encouraging results 
suggest that the two types of delivery systems evaluated here can enhance anticancer 
activity, reduce or even abrogate toxicity, leading to prolonged survival if administered 
using an appropriate dosing schedule. 
 
CONCLUSION 
Much effort has been invested in the quest for the best ligand for selective targeting of 
DDS to a tumor tissue. However, a more pressing question arising – is whether it is 
effective at all to use a specific targeting moiety and if so, can we generalize this approach 
to various DDS? This study constitutes the first side-by-side comparison of two receptor-
targeted ligand-bearing systems, evaluating a polymeric versus a liposomal system in the 
same models. Via a simple and effective chemical protocol, it is possible to conjugate 
folic acid to different nanocarriers, maintaining the binding affinity of the ligand to the 
folate receptor, and exploiting its targeting properties to promote the internalization of the 
carriers. The four formulations designed display potent in vivo pharmacological activity 
while reducing the toxic effects of the free drug.  
FR-targeted polymer therapeutics and liposomal formulations can serve as precision 
nanomedicines for the treatment of a variety of cancers and other difficult-to-treat 
diseases where overexpression of the folate receptor occurs, such as polycystic kidney 
disease, and inflammatory diseases. For polymeric constructs, the dosing regimen and 
the dosing intensity strongly affect the therapeutic index and reveals a major therapeutic 
advantage for the FR-targeted formulation.  
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Table I: Chemical composition of the pullulan conjugates 
 (NH2-PEG)-Pull-(Cyst-Dox) (FA-PEG)-Pull-(Cyst-Dox) 
Composition (% w/w)  (mol %) (% w/w) (mol %)  
Glucose 33.7 53.4 29.1 49.3  
Derivatized 
glucose 
14.7 23.4 12.6 21.3  
1.9 kDa PEG(NH2)2 42.3 6.4 40.4 6.5  
Cysteamine 5 14.4 4.7 14.5  
Doxorubicin 4.3 2.1 6.3 3.4  
Folic Acid - - 6.9 4.8  
 
 
Table II: Chemical composition of the liposomal formulations 
 PLD PLD-FA 
Composition  (mg/mL)  (mol%)  (mg/mL)  (mol%)  
m-PEG-DSPE 3.19 4.56 3.19 4.57  
Cholesterol 3.19 32.51 3.19 32.64  
HPSC 9.58 50.53 9.58 48.60  
Doxorubicin 2 14.46 1.91 13.87  
Folic acid - - 0.034 0.3  
 






(Cyst-Dox) PLD PLD-FA 
Theoretical 
Molecular weight 155 kDa 162 kDa - - 
Hydrodynamic 
volume 
24.3 ± 5.3 nm 
(3.3%) 
144.8 ±65.15 nm 
(96.7%) 
16.6 ± 3 nm 
(1.5%) 
96.8 ±44.6 nm 
(98.5%) 
84.5 nm  
(*PDI = 0.053) 
79.6 nm  
(*PDI = 0.115) 
Zeta potential -4.94 mV -5.43 mV -7.73 mV - 9.75 mV 






Table IV: IC50 on KB HiFR cells and on HUVEC 
 Long-term exposure          (72 h) 
Short-term exposure          
(1 h+72 h) 








HUVEC    
(nM) 
Dox 0.4 1 50 150 
(FA-PEG)-Pull-(Cyst-Dox) 20 20 4000 800 
(NH2-PEG)-Pull-(Cyst-Dox) 2000 400 20000 30000 
PLD-FA 200 150 4000 400 












Figure 2 - Folated nanocarriers compete with FA for the internalization to FR- 
overexpressing cells to which they are rapidly internalized. (A) HUVEC, LoFR-KB and HiFR-
KB cells were incubated with 0.2 µM [3H]FA alone or with cold non-radiolabelled FA, (FA-PEG)-
Pull-(Cyst) or PL-FA at 2 µM FA-equivalent. [3H]FA is internalized by HiFR-KB cells, while the 
internalization is negligible in the subline cultured in regular medium, i.e. LoFR-KB cells (p<10-6). 
The intracellular radioactivity dramatically decreases when the HiFR-KB cells are treated with 
cold FA, (FA-PEG)-Pull-(Cyst) or PL-FA (p<10-9) competing on the binding to the FR. HUVEC 
shows no internalization of the radioactive FA. (B) HiFR-KB cells were incubated with Dox, with 
(FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD-FA or PLD at 200 nM Dox-
equivalent in FF-RPMI. The (FA-PEG)-Pull-(Cyst-Dox) conjugated with folic acid is internalized 
after 5 min, and after 30 min the released Dox is in the nucleus, as colocalization with DAPI 
occurs. PLD-FA is internalized after 4 h, and the internalization of (NH2-PEG)-Pull-(Cyst-Dox) and 





Figure 3 - Folic acid conjugation to nanosystems increase the activity of drug carriers 
compared with the non-folated ones on HiFR-KB cells and HUVEC treated for prolong and 
short-term exposure. HiFR-KB cells exposed to a serial dilution of Dox, (FA-PEG)-Pull-(Cyst-
Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD-FA or PLD for (A) long-term (72 h)  (IC50 of non-folated 
pullulan was higher than folated pullulan bioconjugate, p<10-4 or for (B) short-term (1+72 h) (IC50 
of non-folated pullulan was higher than folated pullulan bioconjugate p<10-7. Anti-proliferative 
activity was evaluated incubating HUVEC with serial dilutions of Dox, (FA-PEG)-Pull-(Cyst-Dox), 
(NH2-PEG)-Pull-(Cyst-Dox), PLD-FA and PLD for (C) Long-term exposure (72 h) (IC50 of non-
folated pullulan was higher than folated pullulan bioconjugate p<10-14, non-folated was higher 
than folated liposome p<10-5) or (D) short-term exposure (1+72 h) (IC50 of non-folated was higher 
than folated pullulan bioconjugate p<10-5, non-folated was higher than folated liposome p<10-5). 





Figure 4 – Three weekly i.v. injections of PLD and PLD-FA maintain and increase the ability 
of Dox to inhibit KB tumor growth in mice. Mice were treated once a week for three weeks 
with Dox, (FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD-FA or PLD at 5 mg/Kg 
Dox-equivalent dose. (A) PLD and PLD-FA inhibited tumor growth compared to saline (p= 0.046), 
(B) did not cause any body weight loss, and (C) prolonged survival compared to saline (Log-rank 





Figure 5 - Three every-other-day i.v. injections of FR-targeted and non-folated polymeric 
and liposomal formulations maintain and increase the ability of Dox to inhibit KB tumor 
growth in mice. Mice were treated three times in 6 days with 5 mg/Kg Dox-equivalent dose of 
Dox, (FA-PEG)-Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD-FA or PLD. (A) All formulations 
inhibited tumor growth while only PLD was significant compared to saline throughout the study, 
p<10-9. Dox, PLD-FA, folated and non-folated pullulan bioconjugates significantly inhibited tumor 
growth by 65%, 87%, 40% and 40%, respectively, till day 20. (B) Enlargement of graph in panel 
A (First 15 days of the experiment). (C) Pullulan bioconjugates did not cause body weight loss 
while liposomal formulations did, however reversible following treatment discontinuation. (D) 
Survival of mice treated with Dox, PLD and PLD was affected by toxic death  during treatment, 
but (E) the overall survival following treatment discontinuation was prolonged compared to saline 




Figure 6 – Six i.v. injections of (FA-PEG)-Pull-(Cyst-Dox) significantly inhibit KB tumor 
growth. Mice were treated six times with 5 mg/Kg of Dox or Dox-equivalent dose of (FA-PEG)-
Pull-(Cyst-Dox), (NH2-PEG)-Pull-(Cyst-Dox), PLD-FA or PLD. (A) (FA-PEG)-Pull-(Cyst-Dox) 
reduced tumor size by 96% compared to saline on day 19 (p<10-12), (B) causing reversible 
moderate body weight loss, and (C) extending survival up to 50 days after the first treatment (Log-





Figure 7 – FR-targeted and non-folated polymeric and liposomal formulations reduce Dox-
induced cardiotoxicity in mice. Mice treated with Dox showed impaired functionality displaying 
(A) greatest left ventricle systolic volume and (B) lowest LV ejection fraction ten days following 
treatment discontinuation. (C) Histological staining with Masson-Trichrome of hearts of mice  
treated three times in 6 days with saline or 5 mg/Kg of Dox or Dox-equivalent dose of PLD-FA, 
PLD, (FA-PEG)-Pull-(Cyst-Dox), or (NH2-PEG)-Pull-(Cyst-Dox). 
 
